Diagnostic BioSystems: Strengthening Cancer Research with Intensive Diagnostic Testing

Dr. Bipin Gupta, Ph.D, Founder, CEO, and CSO

The world of healthcare currently has its hands completely tied around the COVID-19 pandemic, and nobody is talking of anything else. Flattening the curve is the need of the hour, no doubt, but everyone’s attention toward the areas of cancer research and patient care today has dwindled significantly. According to Dr. Bipin Gupta, Ph.D. in zoology and biotechnology expert, the number of biopsies and other immunohistochemistry (IHC) diagnostic testing for non-emergency oncology-related cases are not being properly prioritized. And his statements are further supported by the researchers at Dana-Farber Cancer Institute, among many others, who posit that the virus has complicated the treatment of cancer patients. However, there is a silver lining, which presents itself in the form of Diagnostic BioSystems, a biotechnology company founded by Dr. Gupta that helps healthcare professionals stay the course in all their IHC research for oncology and general diagnostics activities.

Diagnostic BioSystems is an ISO13485:2016 certified manufacturer of medical devices and solutions, established in 1994. Since then, the company has been successfully leveraging the best innovations in the field of pharmaceuticals and diagnostics to offer the most comprehensive and cost-effective products that streamline research workflows, which traditionally are labor-intensive.

Owing to the size and depth of its value chain, Diagnostic BioSystems is perfectly positioned to collaborate with its clients personally and drive customer experience to a whole new level


The company delivers a fully-automated slide staining system with its HighLighter Automated Slide Stainer platform that eliminates the need to stain tissue biopsies manually and accelerates the analysis of each sample. “Researchers need a broad range of antibodies to diagnose cancer and there are no gold standards: a particular antibody cannot confirm the presence of a tumor,” explains Dr. Gupta. The aptly named device helps improve the diagnostic probability of identifying an undifferentiated tumor among patients and then supports pathologists in expediting various antibody tests. In addition to the HighLighter, the company also provides labs with a slew of prediluted antibodies that are ready-to-use and optimized to deliver high-quality staining for all IHC applications.

The company also maintains wellkept relationships with several medical OEMs across the globe, which enables Dr. Gupta and his experienced team to offer customizable products at incredible prices. Owing to the size and depth of its value chain, Diagnostic BioSystems is perfectly positioned to collaborate with its clients personally and drive customer experience to a whole new level.
“We are always able to offer our undivided attention to each lab. This has empowered us to work with large CLIA-certified labs in Europe to improve not only their research competencies but also sales-related operations,” adds Dr. Gupta.

Diagnostic BioSystems is currently a major supplier of biotechnology solutions for several companies in the US, and this has allowed the company to gather vital insights about the various challenges a lab faces and how it attempts to regain control. In the midwest regions of the country, there are a lot of gastrointestinal (GI) studies wherein many researchers are known to struggle with testing for Helicobacter pylori, a type of bacteria that causes GI cancer. With the help of Diagnostic BioSystems’ IHC reagent solutions, professionals in labs witness a dynamic transformation in their approach to testing and improvement in biomarking activities for all GI-related cancer cells.

With such inventive and highly specialized solutions to support oncology research, the company is at the forefront of innovation in the field. Diagnostic BioSystems currently has offices in the US, India, Mexico, and Germany to drive international collaboration and progress in IHC research. Moving forward, the company intends to further invest in automation technologies to increase its instrumentation capabilities and offer the highest standards of biotechnology while retaining its ability to deliver them at reasonable prices.